

Peptide-Based Therapeutics in Fungal Infections: Challenges and Innovations

¹Rinki Vishwas*

¹IIMT College of Medical Sciences, IIMT University, Ganga Nagar (250001), Meerut, Uttar Pradesh, India

Keywords

Peptide-based therapeutics, antifungal, bioavailability, membrane disruption, antimicrobial peptides, drug delivery systems.

Abstract

In light of the growing resistance to antifungal medications, peptide-based therapies have become a viable substitute for treating fungal infections. These peptides, derived from various natural sources or synthesized in the laboratory, exhibit unique mechanisms of action, such as membrane disruption, inhibition of fungal metabolism, and modulation of immune responses. Despite their potential, several challenges remain, including issues with stability, bioavailability, and selectivity. Advances in peptide design, including the cyclization and the addition of artificial amino acids, have improved their therapeutic properties. Additionally, novel delivery systems, such as nanoparticles and liposomes, are being explored to enhance the efficacy and targeted delivery of these peptides. This review explores the characteristics, applications, and challenges of peptide-based antifungal therapies, while also discussing recent innovations in the field. With continued research and development, peptide-based therapeutics could offer a significant contribution to the treatment of fungal infections.

*Corresponding Author

Rinki Vishwas (rinkivishwas34@gmail.com)

Article Info

Received 16 October 2024, Received in revised form 29 November 2024, Accepted 31 December 2024

Available online 20 January 2025

XXXX-XXXX/The authors © 2025, under exclusive licence to the Sprout Publication

[DOI](#)

1. Introduction

Fungal infections, which affect millions of people annually, have become a major worldwide health problem. These infections range from superficial ailments, such as athlete's foot and ringworm, to life-threatening systemic diseases like invasive aspergillosis and candidemia. The burden of fungal infections is particularly severe among immunocompromised individuals, such as those undergoing chemotherapy, organ transplantation, or living with HIV/AIDS [1]. Despite their substantial impact, fungal infections remain underdiagnosed and underreported, largely due to limited awareness and diagnostic challenges. Compounding this issue is the increasing prevalence of drug-resistant fungal strains, which have rendered many conventional antifungal therapies less effective. The rise in antifungal resistance, coupled with the limited arsenal of

currently available antifungal agents, underscores an urgent need for innovative therapeutic approaches [2]. Conventional antifungal treatments, including azoles, echinocandins, and polyenes, have been the mainstay of fungal infection management for decades. While these agents have demonstrated efficacy in treating a broad spectrum of fungal pathogens, they are not without limitations. Many antifungal drugs exhibit significant toxicity, leading to adverse effects that restrict their therapeutic potential [3]. For instance, amphotericin B, a potent polyene antifungal, is associated with nephrotoxicity, while azoles like voriconazole can cause hepatotoxicity and neurological side effects. Moreover, the efficacy of these drugs is further compromised by the emergence of resistant fungal strains, such as *Candida auris*, which has shown resistance to multiple drug classes. These limitations have highlighted the need for novel antifungal agents that can overcome the challenges

posed by resistance and toxicity while providing effective and targeted treatment [4].

Peptide-based therapeutics represent a promising alternative to traditional antifungal drugs, owing to their unique mechanisms of action and distinct advantages. These therapeutics, composed of short chains of amino acids, exert antifungal effects primarily through direct interactions with fungal cell membranes [5]. Unlike conventional drugs that typically target enzymatic pathways, peptides disrupt the structural integrity of the fungal cell membrane, which results in cell death and intracellular contents leaking out. This mechanism offers a significant advantage as it reduces the likelihood of resistance development. Fungal resistance often arises from genetic mutations that alter drug targets; however, the membrane-targeting action of peptides involves physical disruption, which is less susceptible to mutational changes [6]. In addition to their unique mode of action, peptide-based therapeutics exhibit broad-spectrum action, which enables them to effectively combat a variety of fungal infections, including multidrug-resistant strains. Their therapeutic promise is further enhanced by their capacity to target fungal cells specifically while preserving mammalian cells. This selectivity is largely due to differences in membrane composition between fungal and mammalian cells. Fungal membranes contain ergosterol, a sterol absent in mammalian membranes, which peptides can exploit for specificity. As a result, peptide-based drugs often demonstrate lower toxicity profiles compared to conventional antifungals, reducing the risk of adverse side effects [7]. Another critical advantage of peptide-based therapeutics lies in their immunomodulatory properties. Some antifungal peptides can enhance the host's immune response, providing an additional layer of defense against infections. By stimulating immune cells and modulating inflammatory pathways, these peptides can complement their direct antifungal effects, offering a dual mechanism of action. This multifaceted approach not only improves treatment efficacy but also holds potential for prophylactic applications, particularly in those with weakened immune systems who are more susceptible to fungal diseases [8].

Moreover, advancements in peptide engineering have expanded the potential of these therapeutics. Modifications to peptide structures, such as Non-natural amino acids have been cyclized and incorporated to increase their stability and bioavailability. These strategies address one of the

primary challenges associated with peptides—their susceptibility to enzymatic degradation. Enhanced stability ensures prolonged therapeutic activity, making peptides more viable for systemic administration. Additionally, engineered peptides is adaptable to display particular qualities, such as increased potency, enhanced selectivity, and reduced immunogenicity, further optimizing their clinical utility [9]. The versatility of peptide-based therapeutics extends to their potential for combination therapies. When used alongside conventional antifungals, peptides can exhibit synergistic effects, enhancing overall efficacy and reducing the required dosage of toxic drugs. This approach not only mitigates side effects but also helps in combating resistance by targeting multiple pathways simultaneously. Such combination strategies are particularly valuable in the treatment of invasive fungal infections, where single-agent therapies often fall short [10]. The objective of this review is to delve into the challenges and innovations surrounding peptide-based antifungal therapies. These therapeutics have demonstrated significant potential in addressing limitations associated with conventional antifungal treatments, but their clinical application is not without obstacles. One of the primary challenges lies in their inherent instability within biological environments, where they are prone to enzymatic degradation. This susceptibility reduces their bioavailability and necessitates the development of protective delivery systems. Furthermore, the high cost of peptide synthesis and production presents an economic barrier, limiting their accessibility and scalability, particularly in resource-constrained settings [11].

Despite these hurdles, advancements in peptide engineering and delivery systems are paving the way for innovative solutions. Structural modifications, like cyclization and the addition of non-natural amino acids, have improved peptide stability, pharmacokinetics, and efficacy. Novel delivery platforms, including nanocarriers and hydrogels, have been developed to protect peptides from enzymatic degradation and enhance their targeted delivery. Additionally, synergistic approaches that combine peptides with traditional antifungals are showing promise in reducing drug resistance and toxicity [12]. This review aims to highlight these critical developments, emphasizing the need for continued interdisciplinary research and collaboration to overcome the technical, economic, and regulatory challenges associated with peptide-based antifungal therapies. By addressing these issues, peptide-based

treatments have the potential to revolutionize the management of fungal infections, offering safer, more effective, and accessible solutions to a growing global health concern [13].

2. Characteristics of Peptide-Based Therapeutics

A potential class of medications for the treatment of fungal infections is peptide-based therapies. Small, naturally occurring compounds known as antimicrobial peptides (AMPs), these peptides have the capacity to interfere with the development and survival of a variety of microorganisms, such as bacteria, viruses, and fungus. The field of peptide-based therapeutics in fungal infections is still evolving, but its potential has already begun to reshape the landscape of antifungal treatment. This class of drugs is garnering attention due to its unique characteristics and the innovative approaches being explored to overcome the challenges of current antifungal therapies [14]. Therapeutic peptides fall into a number of groups according to their structure, function, and place of origin. A range of species, including microbes, plants, and mammals, create AMPs—naturally occurring peptides—as a component of their innate immune system. Usually, these peptides have a wide range of efficacy against fungus as well as other diseases. Another key category includes synthetic and engineered peptides, which are designed and synthesized in laboratories. These peptides can be optimized for specific targets, improving their effectiveness and stability. Synthetic peptides often take inspiration from naturally occurring AMPs but are modified to enhance their properties, such as antimicrobial activity, selectivity, and resistance to degradation [15]. The mechanism of action of peptide-based therapeutics in fungal infections is multifaceted. One of the primary ways these peptides exert their antifungal effects is through the disruption of fungal membranes. Many AMPs possess amphipathic characteristics, indicating that they have both hydrophilic (which attracts water) and hydrophobic (which repels water) areas in their structure. When these peptides come into contact with the fungal cell membrane, they can insert themselves into the lipid bilayer, forming pores or channels that disrupt the integrity of the membrane [16]. Cell death results from this disturbance, which causes the contents of the cell to spill out. Some peptides are also capable of inducing membrane destabilization by interacting with membrane proteins, further compromising the membrane's function. This mechanism of action is particularly effective against

fungal species that rely heavily on membrane integrity for their survival [17].

In addition to membrane disruption, peptide-based therapeutics can target intracellular pathways essential for fungal growth and survival. Many peptides are capable of entering the cell and engaging with targets inside the cell, such as enzymes, proteins, and nucleic acids. For example, some peptides inhibit the synthesis of key molecules involved in cell wall formation, disrupting the structural integrity of the fungal cell. Others may interfere with critical metabolic pathways, preventing the fungus from acquiring the necessary nutrients for growth and replication. By targeting these essential pathways, peptide-based therapeutics can effectively halt fungal growth and promote cell death, providing an additional layer of therapeutic potential [18]. There are several advantages to using peptide-based therapeutics in order to treat fungal infections. One of the most notable benefits is their broad-spectrum activity. Many AMPs exhibit ability to combat a broad range of fungus species, including pathogenic fungi responsible for infections in humans, such as *Candida*, *Aspergillus*, and *Cryptococcus* [19]. This broad spectrum of activity makes peptide-based therapeutics highly versatile, as they can be used to treat a diverse range of fungal infections without the need for multiple, targeted treatments. This is particularly advantageous in clinical settings where infections may be caused by an unknown or mixed fungal pathogen, allowing clinicians to deploy peptide-based therapies as a first-line defense [20]. Another significant advantage is the reduced risk of resistance development. Traditional antifungal medications, including echinocandins and azoles, often face challenges related to the development of resistance over time. Fungal pathogens can acquire mutations or adapt their mechanisms of action to evade the effects of these drugs, leading to treatment failures. However, peptide-based therapeutics exhibit a different mechanism of action that is less prone to resistance development [21]. This is due in part to their ability to target multiple sites within the fungal cell, including the membrane, intracellular proteins, and nucleic acids, making it more difficult for the fungus to develop resistance to all of these targets simultaneously. Additionally, the innate immune-like nature of AMPs means that they are often less susceptible to the typical resistance mechanisms employed by pathogens against conventional drugs [22].

Notwithstanding these benefits, a number of obstacles need to be removed before the full promise of peptide-based treatments for fungal diseases can be realized. One of the primary obstacles is the stability of peptides in the body. Many peptides are prone to degradation by proteases, enzymes that break down proteins, which can reduce their effectiveness [23]. Additionally, peptides often face challenges related to poor bioavailability, meaning they may not be efficiently absorbed into the bloodstream when administered orally. To overcome these challenges, researchers are exploring various strategies to enhance the delivery and stability of treatments based on peptides. This includes modifying the peptide structure to make it more resistant to degradation, developing formulations that enhance peptide absorption, and exploring alternative methods of administration, such as topical or intranasal delivery [24]. Another challenge lies in the potential toxicity of peptide-based therapeutics. While AMPs are generally considered safe due to their natural origins and selective toxicity towards pathogens, they can still pose a risk to human cells, particularly at higher concentrations. The amphipathic nature of many peptides, which allows them to disrupt microbial membranes, can also lead to the disruption of human cell membranes. Researchers are working to fine-tune the balance between antifungal potency and host cell safety, ensuring that peptides target fungal cells specifically without harming host tissues. This may involve engineering peptides to enhance their selectivity or developing delivery systems that limit exposure to healthy cells [25].

Innovations in peptide-based therapies are developing quickly in spite of these obstacles. The stability, efficacy, and safety of these medications are being enhanced by developments in peptide synthesis, molecular engineering, and delivery methods. For instance, there is potential to increase the therapeutic potential of peptide-based antifungals through the creation of peptoid-based therapies, which are synthetic analogs of peptides that are more resistant to protease degradation. Furthermore, scientists are looking at using liposomes and nanoparticles as peptide delivery vehicles, which might enhance the medications' bioavailability and tailored delivery to fungal infections [26].

3. Challenges in Developing Peptide-Based Antifungal Therapies

Developing peptide-based antifungal therapies presents a range of challenges that need to be addressed before these treatments can be widely used

in clinical settings. One of the primary obstacles is the stability and bioavailability of peptides. Many peptides, particularly those that are naturally occurring, are highly susceptible to enzymatic degradation in the body. Enzymes such as proteases can rapidly break down peptides, rendering them ineffective before they reach the site of infection [27]. This degradation limits their therapeutic potential and requires the development of strategies to protect the peptides from such enzymatic breakdown. Furthermore, peptides often have poor systemic stability and short half-lives, which makes them difficult to maintain at therapeutic concentrations in the bloodstream. The challenge of improving stability involves not only protecting peptides from enzymatic degradation but also enhancing their resistance to the harsh conditions in the gastrointestinal tract, should they be taken orally, or optimizing their absorption when delivered through alternative methods [28]. Another significant challenge in the development of peptide-based antifungal therapies is their potential toxicity and lack of selectivity. While these peptides are effective against fungi, many of them also have activity against human cells, particularly at higher concentrations. This poses a risk of off-target effects, where the peptide could disrupt the membranes of host cells, leading to toxicity [29]. Human cells, like fungal cells, have membranes made of lipids, and the amphipathic nature of many antifungal peptides can cause them to interact with and damage these host cell membranes. Achieving selectivity for fungal cells over host cells is a major hurdle, as fungi and human cells share some structural similarities. Researchers must develop strategies to enhance the selectivity of peptides, ensuring that they target fungal pathogens without causing harm to human tissues. This could involve modifying peptide structures or engineering delivery systems that release peptides specifically at the site of infection [30]. The cost of producing peptide-based therapeutics also remains a significant barrier to their widespread use. Peptides are often synthesized through chemical processes, which can be expensive and labor-intensive. Large-scale production of peptides is challenging due to the complexities involved in their synthesis and purification. While advances in peptide synthesis techniques may reduce some of the costs, scaling up production for clinical use still presents logistical and financial challenges. High production costs can also impact the affordability and accessibility of these therapies, limiting their use in resource-limited settings [31].

In addition to these challenges, the delivery systems used to administer peptide-based antifungal therapies

present further difficulties. One of the primary issues is the difficulty peptides face in crossing biological barriers. The skin, mucosal membranes, and blood-brain barrier (in the case of systemic infections) act as formidable obstacles to the effective delivery of therapeutic peptides. Peptides often cannot penetrate these barriers efficiently, reducing their effectiveness when attempting to treat infections in deeper tissues or systemic infections. Furthermore, peptides may lose their efficacy during the delivery process, as they may degrade or be inactivated before reaching their intended target. Developing effective delivery systems that can protect peptides during transit and ensure their targeted release at the site of infection is a critical challenge. For systemic infections, achieving therapeutic concentrations at the site of infection while avoiding off-target effects in healthy tissues remains a complex problem [32].

Despite these obstacles, research is still being done to find ways to get beyond them using developments in peptide engineering, formulation, and delivery systems. To increase the effectiveness, safety, and affordability of peptide-based antifungal treatments, solutions such as peptide alterations, the addition of protective carriers, and the creation of innovative drug delivery systems are being actively investigated. These treatments have the potential to completely transform the way fungal infections are treated in the future with further development [33].

4. Innovations in Peptide-Based Therapeutics

4.1. Design and Engineering of Peptides

Recent advancements in peptide-based therapeutics for fungal infections have focused on the development of synthetic peptides with enhanced properties. Synthetic peptides offer the advantage of being customizable, allowing researchers to modify their sequence, structure, and properties to optimize antimicrobial activity. By altering the amino acid composition and length, synthetic peptides can be tailored to improve their interaction with fungal targets, enhance their stability, and reduce off-target effects. These peptides are often designed to possess potent antifungal activity against a broad spectrum of pathogens while minimizing the risk of resistance [34]. Cyclization and peptide modifications are also crucial strategies for improving the stability and effectiveness of peptide-based therapeutics. Linear peptides, while potent, are often prone to enzymatic degradation, reducing their therapeutic lifespan. Cyclization—connecting the peptide's terminal ends to form a ring—helps to protect the peptide from enzymatic cleavage and enhances its structural

stability. Additionally, modifications such as incorporating unnatural amino acids, adjusting the hydrophobicity, or introducing disulfide bonds can improve the peptide's resistance to degradation, increase its bioavailability, and enhance its overall stability. These innovations allow for the creation of peptides with more favorable pharmacokinetics and therapeutic outcomes [35].

4.2. Peptide Delivery Systems

Peptide delivery remains a significant challenge in the development of effective antifungal therapies. However, innovations in delivery systems are making strides toward improving the clinical application of peptide-based drugs. Nanoparticles, liposomes, and hydrogels have emerged as promising carriers for targeted peptide delivery. Nanoparticles, due to their small size, can efficiently penetrate biological barriers and deliver peptides directly to the site of infection [36]. By incorporating peptides into nanoparticles, the stability and bioavailability of the peptides are enhanced, and their release can be controlled for sustained therapeutic effects. Similarly, liposomes—lipid-based vesicles—can encapsulate peptides, offering protection against enzymatic degradation and improving their ability to target fungal cells. Hydrogels, which can be applied topically, provide a useful approach for delivering peptides to mucosal surfaces or skin infections, ensuring prolonged contact and release of the therapeutic agent [37]. Transdermal and mucosal delivery approaches are also being explored to improve peptide delivery for localized fungal infections. Transdermal systems aim to deliver peptides through the skin, which could be particularly useful for treating superficial fungal infections such as those caused by *Candida* or *Dermatophytes*. Mucosal delivery, targeting the respiratory, gastrointestinal, or urogenital tracts, is another promising approach for treating systemic or mucosal fungal infections. Specialized formulations such as nanoemulsions or mucosal patches can facilitate the absorption of peptides through these barriers, improving their efficacy and reducing systemic side effects [38].

4.3. Combination Therapies

Combination therapies are becoming increasingly important in the development of peptide-based antifungal treatments. One of the most promising strategies is combining peptides with existing antifungal agents, such as azoles or echinocandins. These combinations can lead to synergistic effects, enhancing the overall antifungal efficacy and potentially overcoming resistance mechanisms that

may limit the effectiveness of conventional treatments. For example, combining a peptide that disrupts the fungal cell membrane with an azole that inhibits ergosterol synthesis could have a more potent effect than either drug alone, leading to faster fungal clearance and reduced risk of resistance development [39]. In addition to combining peptides with traditional antifungals, integrating peptide-based therapeutics with immune-modulating agents is This combination approach can provide a dual mechanism of action, targeting the pathogen directly

another promising approach. Fungal infections often lead to immune suppression or evasion, making it difficult for the host immune system to clear the infection effectively. By incorporating immunomodulatory agents—such as cytokines or immune checkpoint inhibitors—alongside antifungal peptides, it is possible to enhance the host's immune response to the infection.

while also boosting the body's defense mechanisms, potentially leading to better clinical outcomes [40].




Figure 1: Molecular Mechanism of Action of Glucagon-like Peptide-1

4.4. Computational Tools and AI in Peptide Design

The use of computational tools and artificial intelligence (AI) is revolutionizing the design and development of peptide-based therapeutics. Bioinformatics, including molecular modeling and structural prediction software, is being used for rational peptide engineering. These tools allow researchers to predict the structure-activity relationship (SAR) of peptides, identify the most promising sequences for antifungal activity, and optimize the peptide's design before synthesizing it. By modeling how peptides interact with fungal membranes and intracellular targets, computational tools help accelerate the design of peptides with

enhanced potency, selectivity, and stability [41]. Machine learning algorithms are also playing a key role in predicting antifungal activity. By analyzing large datasets of known AMPs, machine learning models can identify patterns in peptide sequences that are correlated with potent antifungal effects. These algorithms can predict the activity of novel peptides based on their amino acid sequence and structural features, significantly reducing the time and cost required for experimental screening. This ability to predict the effectiveness of peptide candidates with high accuracy allows for a more targeted approach in the design process and increases the likelihood of discovering effective new therapies for fungal infections [42].

Table 1: Peptide-Based Antifungal Therapeutics: Preparation, Mechanism, Bioavailability, and Applications

S. No.	Peptide Preparation Name	Method of Preparation	Mode of Action	Bioavailability	Application	References
1	Nisin	Produced via fermentation of <i>Lactococcus lactis</i>	Disrupts cell membranes by binding to lipid II	Oral and systemic availability	Oral infections, food preservation	[43]
2	LL-37	Synthetic peptide from human cathelicidin	Membrane disruption, immune modulation	Moderate	Skin infections, wound healing	[44]
3	Cecropin A	Isolated from <i>Hyalophora cecropia</i> and synthesized	Disrupts fungal membranes	Low	Fungal infections, topical applications	[45]
4	Histatin 5	Isolated from human saliva, synthetic forms available	Inhibits fungal metabolism and membrane function	Low	Oral candidiasis, systemic infections	[46]
5	Thionin	Isolated from plant sources, synthetic variants available	Membrane destabilization	Low	Antifungal, anticancer	[47]
6	Magainin 2	Isolated from <i>Xenopus laevis</i> , synthetic versions available	Disrupts fungal cell membranes	Moderate	Fungal infections, skin infections	[48]
7	Indolicidin	Synthetic peptide derived from bovine neutrophils	Membrane disruption, bacterial killing	Low	Antimicrobial, antifungal	[49]
8	Dermaseptin	Isolated from <i>Dermatophilus</i> species	Membrane disruption	Low	Wound infections, topical	[50]
9	Parasin I	Isolated from <i>Paracymus</i> species	Membrane permeabilization	Low	Topical fungal infections	[51]
10	Pexiganan	Synthesized from magainin peptide analog	Disrupts fungal membranes	Moderate	Skin infections, topical use	[52]
11	Tachyplestin	Isolated from <i>Tachypleus tridentatus</i>	Membrane disruption, pore formation	Low	Antifungal, antimicrobial	[53]
12	Dermcidin	Isolated from human sweat	Membrane permeabilization	Low	Skin infections, wound healing	[54]
13	Bacitracin	Synthesized, isolated from	Cell wall inhibition	Moderate	Topical use for skin	[55], [56]

		Bacillus subtilis			infections	
14	Apidaecin	Isolated from Apis mellifera	Inhibition of protein synthesis	Moderate	Antifungal, antimicrobial	[57], [58]
15	Papiliocin	Isolated from Papilio xuthus	Membrane disruption	Low	Antifungal, topical application	[59]
16	Pisum sativum defensin (PsD)	Isolated from pea plant seeds	Membrane disruption, cell wall synthesis inhibition	Low	Antifungal, antibacterial	[60]
17	Scorpion venom peptides	Isolated from scorpion venom	Membrane disruption, pore formation	Low	Antifungal, pain management	[61]
18	Clavanin	Isolated from Clavibacter michiganensis	Membrane disruption	Low	Antifungal, antibacterial	[62]
19	Daptomycin	Semi-synthetic from Streptomyces roseosporus	Membrane binding and disruption	Moderate	Gram-positive bacterial and fungal infections	[63]
20	Insect defensin	Isolated from insect species, synthetic forms available	Membrane disruption	Low	Topical antifungal	[64], [65]
21	Lacticin 3147	Produced by Lactococcus lactis	Disrupts cell membranes	Oral and systemic availability	Food preservation, oral infections	[66]
22	Fusafungin	Isolated from Fusarium species	Disrupts cell membrane function	Low	Respiratory infections	[67], [68]
23	Microcins	Isolated from Escherichia coli	Disrupts DNA and RNA synthesis	Low	Antifungal, antimicrobial	[69]
24	Nisin Z	Produced by Lactococcus lactis	Disrupts cell membrane and lipid II	Oral and systemic availability	Food preservation, antimicrobial	[66], [70]
25	LL-23	Modified from LL-37	Membrane disruption, immune modulation	Moderate	Systemic infections, wound healing	[71]
26	Tryptophan-rich peptide (TRP)	Synthetic derivation	Membrane interaction and disruption	Low	Topical antifungal	[72]
27	Amyloid β -derived peptide	Synthesized from amyloid precursor protein	Disrupts fungal membrane	Low	Alzheimer's disease, antifungal	[73]
28	Plectasin	Isolated from Pseudoplectania species	Disrupts fungal cell wall	Moderate	Antifungal, veterinary medicine	[74], [75]
29	Chitosan-derived	Synthesized from chitosan	Disrupts cell membrane and	Moderate	Wound healing,	[76]

	peptide		wall		fungal infections	
30	Fusidic acid peptides	Derived from Fusidium species	Inhibits protein synthesis	Low	Antifungal, antimicrobial	[77]
31	Penetratin	Synthetic peptide from <i>Drosophila melanogaster</i>	Enhances membrane permeability	Moderate	Antifungal, antimicrobial	[78], [79]
32	Cationic antimicrobial peptide (CAP)	Synthetic, designed from various sources	Membrane disruption	Low	Antifungal, antibacterial	[80], [81]
33	Defensin-1	Isolated from <i>Homo sapiens</i>	Membrane binding and pore formation	Low	Antifungal, immune defense	[82]
34	Candidacin	Isolated from <i>Candida</i> species	Disrupts fungal cell wall	Moderate	Systemic fungal infections	[83]
35	Temporin A	Isolated from <i>Rana temporaria</i>	Membrane disruption	Low	Antifungal, topical use	[84]
36	Lactoferricin	Isolated from human milk	Iron-binding and membrane disruption	Moderate	Antifungal, immune modulation	[85]
37	Buforin II	Isolated from <i>Bufo bufo</i>	Membrane disruption	Low	Antifungal, antibacterial	[86]
38	Antimicrobial peptide (AMP-5)	Synthesized from various sequences	Membrane disruption	Low	Topical antifungal	[87]
39	Plectasin-derived peptide	Modified from plectasin peptide	Disrupts cell wall and membrane	Low	Systemic fungal infections	[88]
40	Enbrel-derived peptide	Synthesized from Etanercept	Inhibits fungal binding	Moderate	Inflammatory fungal diseases	[89]

5. Applications of Peptide-Based Therapeutics in Fungal Infections

5.1. Common Fungal Infections Targeted

Peptide-based therapeutics are being explored for the treatment of several common fungal infections, offering new avenues for addressing these pervasive diseases. One of the primary targets for peptide-based antifungal therapies is *Candida* species, which are responsible for a variety of infections, including candidiasis. *Candida* is a genus of fungi that commonly causes infections in immunocompromised individuals, particularly those with diabetes, cancer, or undergoing antibiotic therapy [90]. These infections can range from minor ones like vaginal yeast infections and oral thrush to more serious

systemic infections like candidemia, which can be fatal. Peptide-based therapies, particularly those targeting the cell membrane and wall of *Candida*, have shown promise in reducing fungal growth and overcoming resistance mechanisms to common antifungal drugs like fluconazole [91]. Another significant fungal pathogen targeted by peptide-based therapeutics is *Aspergillus* species, which cause aspergillosis. *Aspergillus* is a genus of fungi that can lead to pulmonary infections, particularly in individuals with compromised immune systems, such as those undergoing organ transplants or chemotherapy. Aspergillosis can manifest as allergic reactions, chronic pulmonary disease, or invasive aspergillosis, the latter of which can spread to other organs and tissues, often with fatal consequences.

Peptides that disrupt the fungal cell membrane or interfere with essential intracellular pathways hold promise for treating these invasive infections, potentially reducing reliance on traditional antifungal agents that often face resistance issues [92].

Cryptococcus species, particularly *Cryptococcus neoformans*, are responsible for causing cryptococcosis, a serious fungal infection mostly impacting people with compromised immune systems, such as those living with HIV/AIDS. The infection often manifests as meningitis, but can also affect the lungs and other organs. Due to the ability of *Cryptococcus* to form encapsulated spores that can evade the immune system, treatment can be challenging. Peptide-based therapeutics targeting the fungal membrane or interfering with the synthesis of the cryptococcal capsule could provide effective treatment options, offering a new approach to combat this often-fatal infection [93].

5.2. Emerging Areas

In addition to the well-established fungal pathogens, peptide-based therapeutics are also being explored in emerging areas, particularly in the treatment of multidrug-resistant fungal strains. The rise of resistance among common fungal pathogens, such as *Candida* and *Aspergillus*, to traditional antifungal agents like azoles, echinocandins, and polyenes, has become a growing concern. Multidrug resistance complicates treatment regimens and limits the effectiveness of current therapies. Peptides, due to their diverse mechanisms of action, offer a promising solution to this problem [94]. Their ability to target multiple pathways within the fungal cell, including membrane disruption, inhibition of vital enzymes, and interference with cell wall synthesis, makes them less prone to the same resistance mechanisms that affect conventional antifungals. As such, peptide-based therapeutics could provide an important alternative for treating infections caused by resistant fungal strains [95]. Another emerging application of peptide-based therapeutics is their use as prophylactic agents. The potential to use peptides to prevent fungal infections before they occur is particularly important in high-risk populations, such as immunocompromised patients, those undergoing organ transplantation, or individuals with prolonged antibiotic use. Prophylactic peptides could help reduce the incidence of invasive fungal infections, preventing serious outcomes before an infection takes hold. These peptides could be administered as a preventive measure, either systemically or topically, depending on the site of potential infection. With the

growing concern about fungal infections in vulnerable populations and the limitations of existing prophylactic treatments, peptide-based therapies may provide an effective tool to address these gaps in current care [96].

6. Preclinical studies

Preclinical research is essential to the development of peptide-based antifungal medications because it provides information on the drugs' safety, effectiveness, and potential for clinical use. Peptides' therapeutic potential is commonly tested in vivo using animal models, which enables scientists to evaluate how well they work to cure fungal infections in live things. These models are invaluable for understanding how peptides interact with the host immune system, their pharmacokinetics, and their overall ability to clear infections. Rodent models, particularly mice and rats, are commonly employed for this purpose, as they allow for controlled experiments on infection dynamics and peptide administration routes. Additionally, animal models enable the monitoring of potential toxicity and adverse effects, which are critical factors for determining the safety of a therapeutic candidate before advancing to clinical trials [97]. In vitro studies, performed in cell cultures or laboratory settings, complement these animal studies by evaluating the direct antifungal activity of peptides against various fungal pathogens. These studies provide a detailed understanding of the peptide's mechanism of action, such as whether it disrupts the fungal cell membrane, inhibits essential pathways, or induces other forms of cell death. In vitro testing can also be used to assess the potential for resistance development, providing valuable data on how fungi might adapt to the presence of the peptide. Key findings from these preclinical studies have shown that peptide-based therapeutics can exhibit potent antifungal activity against a wide range of fungal species, including *Candida*, *Aspergillus*, and *Cryptococcus*, with some peptides demonstrating superior efficacy when compared to traditional antifungal drugs. Furthermore, peptides have shown promise in overcoming resistance issues that are common with conventional treatments [98].

In terms of clinical trials, several peptide-based antifungal candidates are currently under investigation, with some showing considerable progress. These candidates are being tested for their safety, efficacy, and pharmacological properties in humans, typically in phases that include early-stage safety trials (Phase I) and later-stage efficacy trials (Phase II and III). A number of peptides have

successfully entered clinical trials, often as standalone treatments or in combination with existing antifungal therapies. One example includes synthetic peptides derived from natural AMPs, which have demonstrated broad-spectrum activity against fungal pathogens in preclinical studies. These peptides are being tested in clinical trials to determine their potential to treat both superficial and systemic fungal infections, with some showing positive early results [99].

However, not all peptide-based candidates have succeeded in clinical development. Some trials have encountered setbacks due to issues with peptide stability, bioavailability, or safety concerns. The rapid degradation of peptides in the human body, as well as challenges with their delivery to the infection site, have posed significant obstacles. Additionally, some peptides have been found to cause off-target effects or toxicity at higher concentrations, leading to the suspension or failure of certain trials. Despite these challenges, the ongoing exploration of alternative formulations, modified peptide structures, and advanced delivery systems continues to show promise. Researchers are also looking at combination therapies involving peptides and existing antifungal agents, which could help mitigate some of these issues by reducing the required dose of peptides or enhancing their effectiveness [100].

The outcomes of preclinical and clinical research to date suggest great promise for peptide-based antifungal treatments, even if they are still in the early phases of clinical development. Continued advancements in peptide engineering, formulation, and delivery systems will be crucial for overcoming the hurdles faced in earlier trials. With successful integration into clinical practice, peptide-based therapeutics could provide a new and powerful weapon in the fight against fungal infections, particularly those that are resistant to conventional treatments [101].

7. Regulatory and Commercialization Challenges

The development of peptide-based antifungal therapeutics faces several regulatory and commercialization challenges that must be addressed to bring these promising treatments to market. Regulatory requirements for peptide drugs are stringent, as health authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require rigorous testing to ensure the safety, efficacy, and quality of any new therapeutic [102]. Peptide therapeutics must go

through the same approval process as other drugs, involving preclinical studies to assess safety and efficacy, followed by clinical trials in human subjects. This process can take years and requires substantial financial investment. Guidelines for the approval of peptide therapeutics are complex and involve ensuring that these peptides are not only effective against the targeted fungal pathogens but also have an acceptable safety profile. Peptides must demonstrate minimal toxicity, no adverse immune responses, and adequate pharmacokinetics. This often requires extensive preclinical and clinical testing to identify and mitigate any potential risks [103]. For antifungal peptides, there are specific challenges that make regulatory approval even more difficult. Many peptide-based antifungal candidates have issues with stability, bioavailability, and delivery that need to be thoroughly addressed before regulatory approval can be granted. The susceptibility of peptides to degradation by enzymes in the body and their difficulty in crossing biological barriers, such as the skin or mucosal membranes, can complicate the demonstration of their clinical effectiveness. Furthermore, peptides often require specialized formulations to improve their pharmacokinetic profiles, which can add complexity to the approval process. Regulators may require extensive data to ensure that these formulations are safe for human use and that the peptides are effective in achieving therapeutic concentrations at the site of infection. Additionally, the development of resistance to peptide-based drugs, although less common than with traditional antifungals, may require specific monitoring and regulatory oversight [104].

On the commercialization front, the market potential for peptide-based antifungal therapies is significant, but the pathway to market success is fraught with challenges. The economic feasibility of producing peptides on a large scale remains a concern. Peptides, especially those synthesized chemically, can be costly to manufacture, and the infrastructure for large-scale production is not as established as for conventional small-molecule drugs. The high cost of production can lead to expensive treatments, which may limit their accessibility, particularly in low-resource settings. Additionally, peptide drugs often require cold-chain storage or specialized delivery systems, which further increase production and distribution costs. These economic hurdles make it challenging for companies to achieve profitability, especially when competing with more affordable, established antifungal treatments [105]. Market competition is another significant challenge. Many established antifungal

drugs, such as azoles, echinocandins, and polyenes, are widely used and have a strong presence in the market. Peptide-based therapeutics will need to demonstrate clear advantages, such as superior efficacy, lower toxicity, or the ability to treat multidrug-resistant fungal strains, in order to gain market share. While peptide therapies offer exciting new possibilities, they must prove their value over existing treatments to attract both healthcare providers and patients. The clinical efficacy and safety profiles of peptide-based therapies must be clearly superior or complementary to current antifungal options to justify their adoption in clinical practice [106].

To overcome these challenges, collaboration between the public and private sectors is essential. Public research institutions, universities, and government agencies can provide funding, research expertise, and regulatory guidance to help accelerate the development of peptide-based antifungal therapies. Partnerships with private pharmaceutical companies can bring in the necessary resources for large-scale production, clinical trials, and distribution. Additionally, public-private collaborations can help streamline regulatory processes and ensure that new peptide therapies reach the market more efficiently. Governments and health organizations may also play a role in incentivizing the development of novel antifungal treatments through grants, tax incentives, and faster approval pathways, particularly in light of the growing threat of antifungal resistance [107]. While the potential for peptide-based antifungal therapies is significant, they face substantial regulatory and commercialization challenges that must be addressed for successful market entry. The path to approval requires rigorous testing to meet safety and efficacy standards, while the economic and competitive landscape demands careful planning to ensure feasibility and profitability. Public and private sector collaboration will be key to overcoming these hurdles and ensuring that peptide-based therapeutics can fulfill their promise as a powerful tool in the fight against fungal infections [108].

8. Future Directions

The future of peptide-based antifungal therapies is filled with exciting possibilities, driven by advances in peptide drug design, novel delivery platforms, and strategies to address global challenges. One of the key areas of advancement in peptide drug design is the incorporation of non-natural amino acids and the development of hybrid peptides. Non-natural amino acids offer increased versatility and stability to

peptides, allowing for more sophisticated modifications that improve their resistance to enzymatic degradation and enhance their overall pharmacological properties. These modifications can also fine-tune the peptide's specificity and potency against fungal targets. Hybrid peptides, which combine elements of AMPs with other bioactive molecules, are also being explored to create multifunctional therapeutics. By designing peptides that not only target fungal pathogens but also modulate the host immune response, these hybrid molecules could provide a more holistic approach to treating fungal infections. This multi-pronged strategy may be particularly useful in combating systemic infections or infections in immunocompromised individuals [109]. Another promising direction is the development of multifunctional peptides that can serve more than one therapeutic role. These peptides could act on multiple targets within the fungal cell, such as disrupting the cell membrane, inhibiting critical enzymes, or interfering with the fungal cell wall. By attacking several aspects of fungal biology simultaneously, multifunctional peptides may reduce the risk of resistance development, which is a growing concern with conventional antifungal therapies. Furthermore, multifunctional peptides could be designed to have dual action, targeting fungal cells while simultaneously enhancing the host's immune response, providing a synergistic effect that improves clinical outcomes. This approach reflects a shift toward more sophisticated, targeted therapies that offer broader therapeutic benefits [110].

To increase the bioavailability and targeted administration of peptides, new delivery systems are being created concurrently with developments in peptide design. One such advance that makes it possible to deliver peptides exactly to the site of infection is the development of smart and responsive delivery systems. These systems may be made to react to certain environmental stimuli, including variations in temperature, pH, or the presence of biomarkers unique to fungi. To reduce side effects and increase treatment efficacy, for example, peptide-loaded liposomes or nanoparticles can be designed to release their payload only when specific microbial signals are present or after they have reached the infected area. In addition to increasing the peptide's effectiveness, this precise delivery lowers the dosage needed, which is essential for reducing toxicity and boosting patient compliance [111]. Additionally, biomaterials are essential for improving the effectiveness of peptide-based treatments. The stability and controlled release of peptides can be enhanced by the use of biomaterials

including hydrogels, bioadhesive polymers, and nanostructures, enabling long-term, maintained therapy. When treating chronic or localized infections, these materials can be modified to improve the pharmacokinetics of peptides, guaranteeing that the therapeutic agent is administered over a prolonged period of time. Additionally, biomaterials can help transfer peptides via biological barriers including the blood-brain barrier, mucosal membranes, or the skin, which makes them effective in treating a variety of fungal infections, including some that are challenging to treat with traditional medicines [112].

Addressing global challenges in the treatment of fungal infections is another critical focus for the future of peptide-based therapeutics. One major challenge is improving accessibility to these treatments in low-income regions, where fungal infections often go untreated due to a lack of affordable and effective therapies. To tackle this issue, strategies must be developed to reduce the production costs of peptide-based drugs, such as optimizing manufacturing processes, scaling up production, and developing cost-effective formulations. Public health initiatives and collaborations with international organizations could help ensure that these treatments are made available at affordable prices in low-income countries, where fungal infections often have the most devastating impact. Furthermore, the use of locally sourced raw materials and the development of more efficient synthesis methods could reduce costs and increase accessibility [113]. The role of global partnerships will be crucial in addressing the growing problem of antifungal resistance, which poses a significant threat to global health. Collaborative efforts between governments, private companies, research institutions, and international health organizations are essential for accelerating the development of new antifungal agents, including peptide-based therapeutics. Global partnerships can also help facilitate the sharing of knowledge, resources, and data, which will enable researchers to tackle the complex issues related to fungal infections more effectively. Moreover, these partnerships can promote the establishment of global surveillance networks to monitor antifungal resistance patterns and guide the development of new treatments. By working together, the global community can ensure that innovative peptide-based antifungal therapies are developed, tested, and distributed in a way that maximizes their impact on public health [114]. The future of peptide-based antifungal therapeutics is bright, with ongoing advances in peptide design, delivery systems, and global strategies to improve access and tackle

resistance. By continuing to innovate in these areas, the potential for peptide-based drugs to revolutionize the treatment of fungal infections is significant, offering hope for improved outcomes, particularly in populations facing the greatest challenges. The continued collaboration across sectors will be key to overcoming obstacles and ensuring that these therapies are accessible, affordable, and effective in the fight against fungal diseases [115].

Conclusion

Peptide-based therapeutics hold significant promise in the treatment of fungal infections, but the journey toward clinical application has been fraught with challenges. Key issues include the stability and bioavailability of peptides, potential toxicity and off-target effects, high production costs, and difficulties in delivering peptides to the site of infection. Additionally, the regulatory hurdles associated with peptide drug approval are substantial, particularly as antifungal peptides must meet rigorous safety and efficacy standards before they can be brought to market. However, despite these challenges, numerous innovations have emerged that offer hope for overcoming these obstacles. Advances in peptide design, including the use of non-natural amino acids and hybrid peptides, have improved stability and potency. Furthermore, novel delivery platforms such as smart, responsive systems and biomaterials-based approaches are enhancing the efficacy and precision of peptide-based therapeutics. These innovations not only address concerns of stability and delivery but also open the door for multifunctional peptides that target multiple aspects of fungal biology and host immune responses. The impact of peptide-based therapeutics on the fungal infection treatment landscape could be profound. With the rise of multidrug-resistant fungal strains, conventional antifungal therapies are increasingly ineffective, and the need for new treatment options has never been more urgent. Peptide-based drugs, with their broad-spectrum activity and unique mechanisms of action, offer a potential solution to this growing crisis. Their ability to target fungal membranes, enzymes, and other critical pathways, combined with their lower propensity for resistance development, positions them as a promising alternative to current therapies. Furthermore, peptide-based therapeutics could help fill critical gaps in the prevention and treatment of infections in vulnerable populations, such as immunocompromised individuals or those at risk of invasive fungal infections. The ability to combine peptides with existing antifungals in combination therapies further enhances their potential to address

complex fungal infections, including those caused by resistant strains. Peptide-based antifungal therapies to fulfill their potential, interdisciplinary research and collaboration are essential. The development of effective peptide drugs requires expertise from a diverse range of fields, including molecular biology, chemistry, pharmacology, and clinical medicine. Researchers from academia, industry, and government must collaborate to optimize peptide design, refine delivery systems, and address the challenges related to toxicity, bioavailability, and cost. Public and private sector partnerships will be particularly important in ensuring that these promising therapeutics are not only developed but also made accessible to global populations, particularly in low-income regions where fungal infections are most prevalent and often go untreated. By combining expertise, resources, and knowledge from various sectors, the global community can accelerate the development of peptide-based therapies and create a more effective, sustainable approach to tackling fungal infections.

In summary, while the road to the widespread use of peptide-based antifungal therapeutics is challenging, the potential rewards are immense. With ongoing innovation in peptide design, delivery mechanisms, and collaborative efforts, peptide-based drugs could

significantly change the landscape of fungal infection treatment. The continued investment in interdisciplinary research and cross-sector collaboration will be critical to realizing the full potential of these novel therapeutics, ultimately improving patient outcomes and helping to combat the growing threat of antifungal resistance.

Acknowledgement

The author expresses gratitude to the IIMT College of Medical Sciences, IIMT University, for their constant support and resources that facilitated this review. Special thanks are extended to colleagues and mentors for their valuable insights and encouragement.

Author Contributions

R.V. conceptualized the review, conducted the literature search, and prepared the manuscript.

Source of Funding

There is no funding available to conduct this study.

Conflicts of Interest

The authors declare that there is no conflict of interest.

References

1. W. Fang et al., –Diagnosis of invasive fungal infections: challenges and recent developments,| *Journal of Biomedical Science*. 2023. doi: 10.1186/s12929-023-00926-2.
2. S. A. Howell, –Dermatopathology and the Diagnosis of Fungal Infections,| *British Journal of Biomedical Science*. 2023. doi: 10.3389/bjbs.2023.11314.
3. Z. Li, G. Lu, and G. Meng, –Pathogenic fungal infection in the lung,| *Front. Immunol.*, 2019, doi: 10.3389/fimmu.2019.01524.
4. Y. Gou, Y. Hu, and W. Wang, –Immunotherapy for fungal infections,| *Chinese J. Appl. Clin. Pediatr.*, 2024, doi: 10.3760/cma.j.cn101070-20230605-00447.
5. J. N. Shah et al., –Peptides-based therapeutics: Emerging potential therapeutic agents for COVID-19,| *Therapies*, 2022, doi: 10.1016/j.therap.2021.09.007.
6. C. Lamers, –Overcoming the Shortcomings of Peptide-Based Therapeutics,| *Futur. Drug Discov.*, 2022, doi: 10.4155/fdd-2022-0005.
7. G. Agarwal and R. Gabrani, –Antiviral Peptides: Identification and Validation,| *International Journal of Peptide Research and Therapeutics*. 2021. doi: 10.1007/s10989-020-10072-0.
8. A. Jash, A. Ubeyitogullari, and S. S. H. Rizvi, –Liposomes for oral delivery of protein and peptide-based therapeutics: challenges, formulation strategies, and advances,| *Journal of Materials Chemistry B*. 2021. doi: 10.1039/d1tb00126d.
9. M. H. Baig et al., –Peptide based therapeutics and their use for the treatment of neurodegenerative and other diseases,| *Biomedicine and Pharmacotherapy*. 2018. doi: 10.1016/j.biopha.2018.04.025.
10. S. Bin Yang, N. Banik, B. Han, D. N. Lee, and J. Park, –Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy,| *Pharmaceutics*. 2022. doi: 10.3390/pharmaceutics14071378.
11. S. Sundar, M. P. Rajan, and S. Piramanayagam, –In Silico Derived Peptides for Inhibiting the Toxin–Antitoxin Systems of Mycobacterium tuberculosis: Basis for Developing Peptide-Based Therapeutics,| *Int. J. Pept. Res. Ther.*, 2019, doi: 10.1007/s10989-018-9792-8.

12. J. Bu et al., –Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis, *Biosens. Bioelectron.*, 2022, doi: 10.1016/j.bios.2022.114445.
13. F. Charih, K. K. Biggar, and J. R. Green, –Assessing sequence-based protein–protein interaction predictors for use in therapeutic peptide engineering, *Sci. Rep.*, 2022, doi: 10.1038/s41598-022-13227-9.
14. Q. Y. Zhang et al., –Antimicrobial peptides: mechanism of action, activity and clinical potential, *Military Medical Research*. 2021. doi: 10.1186/s40779-021-00343-2.
15. T. Samec, J. Boulos, S. Gilmore, A. Hazelton, and A. Alexander-Bryant, –Peptide-based delivery of therapeutics in cancer treatment, *Materials Today Bio*. 2022. doi: 10.1016/j.mtbio.2022.100248.
16. T. Farhadi and S. M. R. Hashemian, –Computer-aided design of amino acid-based therapeutics: A review, *Drug Design, Development and Therapy*. 2018. doi: 10.2147/DDDT.S159767.
17. M. J. Uddin et al., –Large scale peptide screening against main protease of SARS CoV-2, *J. Comput. Chem.*, 2023, doi: 10.1002/jcc.27050.
18. E. Kondo, H. Iioka, and K. Saito, –Tumor-homing peptide and its utility for advanced cancer medicine, *Cancer Science*. 2021. doi: 10.1111/cas.14909.
19. A. Altiti et al., –Thiocarbamate building blocks enable the construction of azapeptides for rapid development of therapeutic candidates, *Nat. Commun.*, 2022, doi: 10.1038/s41467-022-34712-9.
20. L. Wei, C. Zhou, R. Su, and Q. Zou, –PEPred-Suite: Improved and robust prediction of therapeutic peptides using adaptive feature representation learning, *Bioinformatics*, 2019, doi: 10.1093/bioinformatics/btz246.
21. L. E. Waggoner, M. I. Madias, A. A. Hurtado, and E. J. Kwon, –Pharmacokinetic Analysis of Peptide-Modified Nanoparticles with Engineered Physicochemical Properties in a Mouse Model of Traumatic Brain Injury, *AAPS J.*, 2021, doi: 10.1208/s12248-021-00626-5.
22. E. J. Oh et al., –Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives, *Journal of Controlled Release*. 2010. doi: 10.1016/j.jconrel.2009.09.010.
23. L. Guo, S. Lin, Z. Chen, Y. Cao, B. He, and G. Lu, –Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines, *Signal Transduction and Targeted Therapy*. 2023. doi: 10.1038/s41392-023-01472-x.
24. L. Diao and B. Meibohm, –Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides, *Clinical Pharmacokinetics*. 2013. doi: 10.1007/s40262-013-0079-0.
25. M. A. Reynolds and M. E. Aichelmann-Reidy, –Protein and peptide-based therapeutics in periodontal regeneration, *J. Evid. Based. Dent. Pract.*, 2012, doi: 10.1016/S1532-3382(12)70023-4.
26. D. Sanjanwala et al., –Polysaccharide-based hydrogels for drug delivery and wound management: a review, *Expert Opinion on Drug Delivery*. 2022. doi: 10.1080/17425247.2022.2152791.
27. A. Matejuk et al., –Peptide-based antifungal therapies against emerging infections, *Drugs of the Future*. 2010. doi: 10.1358/dof.2010.035.03.1452077.
28. Sonesson, L. Ringstad, E. Andersson Nordahl, M. Malmsten, M. Mörgelin, and A. Schmidtchen, –Antifungal activity of C3a and C3a-derived peptides against *Candida*, *Biochim. Biophys. Acta - Biomembr.*, 2007, doi: 10.1016/j.bbamem.2006.10.017.
29. G. B. De Cesare, S. A. Cristy, D. A. Garsin, and M. C. Lorenz, –Antimicrobial peptides: A new frontier in antifungal therapy, *MBio*, 2020, doi: 10.1128/mBio.02123-20.
30. D. K. Mercer and D. A. O’Neil, –Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response, *Frontiers in Immunology*. 2020. doi: 10.3389/fimmu.2020.02177.
31. Popa, X. Shi, T. Ruiz, P. Ferrer, and M. Coca, –Biotechnological production of the cell penetrating antifungal PAF102 peptide in *pichia pastoris*, *Front. Microbiol.*, 2019, doi: 10.3389/fmicb.2019.01472.
32. S. S. Rathnam, T. Deepak, B. N. Sahoo, T. Meena, Y. Singh, and A. Joshi, –Metallic Nanocarriers for Therapeutic Peptides: Emerging Solutions Addressing the Delivery Challenges in Brain Ailments, *Journal of Pharmacology and Experimental Therapeutics*. 2024. doi: 10.1124/jpet.123.001689.
33. M. Shukla, P. Chandley, and S. Rohatgi, –The role of b-cells and antibodies against candida vaccine antigens in invasive candidiasis, *Vaccines*. 2021. doi: 10.3390/vaccines9101159.
34. Ya’u Sabo Ajingi and Nujarin Jongruja, –Antimicrobial Peptide Engineering: Rational Design, Synthesis, and Synergistic Effect, *Russian Journal of Bioorganic Chemistry*. 2020. doi: 10.1134/S1068162020040044.
35. P. Ernst and A. Plückthun, –Advances in the design and engineering of peptide-binding repeat proteins, *Biological Chemistry*. 2017. doi: 10.1515/hsz-2016-0233.
36. Berillo, A. Yeskendir, Z. Zharkinbekov, K. Raziyeva, and A. Saparov, –Peptide-based drug delivery systems, *Medicina (Lithuania)*. 2021. doi: 10.3390/medicina5711209.
37. J. Yang, H. W. An, and H. Wang, –Self-Assembled Peptide Drug Delivery Systems, *ACS Applied Bio Materials*. 2021. doi: 10.1021/acsabm.0c00707.

38. Y. Islam et al., –Peptide based drug delivery systems to the brain,| *Nano Express*. 2020. doi: 10.1088/2632-959X/ab9008.
39. S. Alven and B. Aderibigbe, –Combination therapy strategies for the treatment of malaria,| *Molecules*. 2019. doi: 10.3390/molecules24193601.
40. A.Okem, C. Henstra, M. Lambert, and R. Hayeshi, –A review of the pharmacodynamic effect of chemo-herbal drug combinations therapy for cancer treatment,| *Medicine in Drug Discovery*. 2023. doi: 10.1016/j.medidd.2022.100147.
41. G. Agüero-Chapin et al., –Emerging Computational Approaches for Antimicrobial Peptide Discovery,| *Antibiotics*. 2022. doi: 10.3390/antibiotics11070936.
42. L. Chang, A. Mondal, B. Singh, Y. Martínez-Noa, and A. Perez, –Revolutionizing peptide-based drug discovery: Advances in the post-AlphaFold era,| *Wiley Interdisciplinary Reviews: Computational Molecular Science*. 2024. doi: 10.1002/wcms.1693.
43. M. R. Edalatian Dovom, M. B. Habibi Najafi, P. Rahnama Vosough, N. Norouzi, S. J. Ebadi Nezhad, and B. Mayo, –Screening of lactic acid bacteria strains isolated from Iranian traditional dairy products for GABA production and optimization by response surface methodology,| *Sci. Rep.*, 2023, doi: 10.1038/s41598-023-27658-5.
44. K. A. Patras et al., – Host Cathelicidin Exacerbates Group B Streptococcus Urinary Tract Infection ,| *mSphere*, 2020, doi: 10.1128/msphere.00932-19.
45. M. Ziaja, A. Dziejdzic, K. Szafraniec, and A. Piastowska-Ciesielska, –Cecropins in cancer therapies-where we have been?,| *European Journal of Pharmacology*. 2020. doi: 10.1016/j.ejphar.2020.173317.
46. Sharee Leong and Shamala Marimuthu, –Molecular characterization of oral bacteria isolated from human saliva,| *Int. J. Res. Pharm. Sci.*, 2021, doi: 10.26452/ijrps.v12i2.4741.
47. J. Acuña, Evaluación limnológica y microbiológica de la Laguna del Quilotoa, provincia de Cotopaxi – Ecuador. 2021.
48. F. W. Schmitges et al., –Attachment-1 copy 2.jpeg.pdf,| *Skelet. Muscle*, 2016.
49. K. Lugardon et al., –Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A,| *J. Biol. Chem.*, 2000, doi: 10.1074/jbc.275.15.10745.
50. N. U. Horadagoda, S. Biasutti, M. Gimeno, and A. Dart, –Dermatophilus congolensis associated bronchopneumonia in an alpaca,| *Vet. Med. Sci.*, 2020, doi: 10.1002/vms3.213.
51. G. H. Horn, – Contributions to a Knowledge of the Curculionidae of the United States,| *P. Am. Phil. Soc.*, 1873.
52. K. Matsuzaki, K. I. Sugishita, M. Harada, N. Fujii, and K. Miyajima, –Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria,| *Biochim. Biophys. Acta - Biomembr.*, 1997, doi: 10.1016/S0005-2736(97)00051-5.
53. J. Li et al., –The Beneficial Effects of Edible Kynurenic Acid from Marine Horseshoe Crab (*Tachypleus tridentatus*) on Obesity, Hyperlipidemia, and Gut Microbiota in High-Fat Diet-Fed Mice,| *Oxid. Med. Cell. Longev.*, 2021, doi: 10.1155/2021/8874503.
54. H. Lin et al., –Differential involvement of glycans in the binding of *Staphylococcus epidermidis* and *Corynebacterium* spp. to human sweat,| *Microbiol. Res.*, 2019, doi: 10.1016/j.micres.2018.12.007.
55. O. Mbagwu, S. H. Auta, M. T. Bankole, A. S. Kovo, and O. P. Abioye, –Biosynthesis and characterization of silver nanoparticles using *Bacillus subtilis*, *Escherichia coli*, and leaf extracts of *Jatropha* and *Ocimum* species,| *Int. Nano Lett.*, 2023, doi: 10.1007/s40089-022-00387-9.
56. Khullar, R. Det-udom, P. Prombutar, and C. Prakitchaiwattana, –Probiogenomic analysis and safety assessment of *Bacillus* isolates using Omics approach in combination with In-vitro,| *LWT*, 2022, doi: 10.1016/j.lwt.2022.113216.
57. M. Carina Audisio, M. J. Torres, D. C. Sabaté, C. Ibarguren, and M. C. Apella, –Properties of different lactic acid bacteria isolated from *Apis mellifera* L. bee-gut,| *Microbiol. Res.*, 2011, doi: 10.1016/j.micres.2010.01.003.
58. P. Nadal-Jimenez et al., –*Arsenophonus apicola* sp. nov., isolated from the honeybee *Apis mellifera*,| *Int. J. Syst. Evol. Microbiol.*, 2022, doi: 10.1099/ijsem.0.005469.
59. J. H. Lee et al., –Deciphering novel antimicrobial peptides from the transcriptome of *papilio xuthus*,| *Insects*, 2020, doi: 10.3390/insects11110776.
60. Z. Moussa et al., –Domiciliation of *Trichoderma asperellum* Suppresses *Globiosporangium ultimum* and Promotes Pea Growth, Ultrastructure, and Metabolic Features,| *Microorganisms*, 2023, doi: 10.3390/microorganisms11010198.
61. M. A. El Hidan, M. A. Laaradia, O. El Hiba, A. Draoui, A. Aimrane, and K. Kahime, –Scorpion-Derived Antiviral Peptides with a Special Focus on Medically Important Viruses: An Update,| *BioMed Research International*. 2021. doi: 10.1155/2021/9998420.
62. S. Z. Berry, G. G. Madumadu, M. R. Uddin, and D. L. Coplin, –Virulence Studies and Resistance to *Clavibacter michiganensis* ssp. *michiganensis* in Tomato Germplasm,| *HortScience*, 2022, doi: 10.21273/hortsci.24.2.362.
63. P. I. Hair and S. J. Keam, –Daptomycin: A review of its use in the management of complicated skin and soft-tissue infections and *Staphylococcus aureus* bacteraemia,| *Drugs*. 2007. doi: 10.2165/00003495-200767100-00008.

64. M. Sepe, I. D. Daud, A. Gassa, and Firdaus, –INFECTIVITY OF *BEAUVERIA BASSIANA* (BALSAMO) AGAINST *TRIBOLIUM CASTANEUM* (COLEOPTERA: TENEBRIONIDAE),*J. Appl. Res. Plant Sci.*, 2020, doi: 10.38211/joarps.2020.1.2.8.
65. O. M. Adeoti, A. H. Bello, O. E. Adedokun, K. A. Komolafe, D. A. Adesina, and O. J. Olaoye, –Distinctive Molecular typing of 16S rRNA of *Bacillus* species isolated from farm settlement.,*Int. J. Immunol. Microbiol.*, 2021, doi: 10.55124/ijim.v1i1.55.
66. S. K. Singh et al., –The Plasmodium falciparum circumsporozoite protein produced in *Lactococcus lactis* is pure and stable,*J. Biol. Chem.*, 2020, doi: 10.1074/jbc.RA119.011268.
67. M. R. Greeff-Laubscher and K. Jacobs, –Fusarium species isolated from post-hatchling loggerhead sea turtles (*Caretta caretta*) in South Africa,*Sci. Rep.*, 2022, doi: 10.1038/s41598-022-06840-1.
68. M. T. Noorabadi et al., –Phylogeny and mycotoxin profile of *Fusarium* species isolated from sugarcane in Southern Iran,*Microbiol. Res.*, 2021, doi: 10.1016/j.micres.2021.126855.
69. M. J. Khong, A. M. Snyder, A. K. Magnaterra, M. M. Young, N. L. Barbieri, and S. L. Weimer, –Antimicrobial resistance profile of *Escherichia coli* isolated from poultry litter,*Poult. Sci.*, 2023, doi: 10.1016/j.psj.2022.102305.
70. P. J. Looijesteijn, L. Trapet, E. De Vries, T. Abee, and J. Hugenholtz, –Physiological function of exopolysaccharides produced by *Lactococcus lactis*,*Int. J. Food Microbiol.*, 2001, doi: 10.1016/S0168-1605(00)00437-2.
71. O. Turkoglu, C. Efeoglu, and H. Atmaca, –Does peri-implant bone loss affect the LL-37 and proteinase 3 levels in peri-implant sulcus fluid?,*Int. J. Implant Dent.*, 2020, doi: 10.1186/s40729-020-00240-8.
72. Sorrentino et al., –Mechano-modulatory synthetic niches for liver organoid derivation,*Nat. Commun.*, 2020, doi: 10.1038/s41467-020-17161-0.
73. R. Kumar, Niharika, K. K. Ojha, H. N. Yadav, N. Sharma, and V. K. Singh, –Investigation of molecular interaction between β -amyloid and insulin receptor: An in-silico study,*Chem. Biol. Lett.*, 2022.
74. C. D. B. Gamage et al., –Libertellenone T, a Novel Compound Isolated from Endolichenic Fungus, Induces G2/M Phase Arrest, Apoptosis, and Autophagy by Activating the ROS/JNK Pathway in Colorectal Cancer Cells,*Cancers (Basel)*, 2023, doi: 10.3390/cancers15020489.
75. Q. Zhang and J. Zhang, –A new species of the genus *Pseudoplectania*, *P. sinica*,*Mycosystema*, 2020, doi: 10.13346/j.mycosystema.200020.
76. A.K. Keerthana and P. M. Ashraf, –Carbon nanodots synthesized from chitosan and its application as a corrosion inhibitor in boat-building carbon steel BIS2062,*Appl. Nanosci.*, 2020, doi: 10.1007/s13204-019-01177-0.
77. Sharma et al., –Fusidic Acid: A Therapeutic Review,*Asian J. Res. Chem.*, 2022, doi: 10.52711/0974-4150.2022.00066.
78. P. Hammel and D. Ungureanu, –RB690, RB691, RB692 and RB693 antibodies recognize a *Drosophila melanogaster* Nop56 peptide by ELISA,*Antib. Reports*, 2022, doi: 10.24450/journals/abrep.2022.e997.
79. Z. Wang, N. Pan, J. Yan, J. Wan, and C. Wan, –Systematic Identification of Microproteins during the Development of *Drosophila melanogaster*,*J. Proteome Res.*, 2022, doi: 10.1021/acs.jproteome.2c00004.
80. M. Erdem Büyükkiraz and Z. Kesmen, –Antimicrobial peptides (AMPs): A promising class of antimicrobial compounds,*Journal of Applied Microbiology*. 2022. doi: 10.1111/jam.15314.
81. Q. Zhang et al., –Islet Encapsulation: New Developments for the Treatment of Type 1 Diabetes,*Frontiers in Immunology*. 2022. doi: 10.3389/fimmu.2022.869984.
82. L. Yu et al., –Epidemiology, molecular characterization, and drug resistance of IncHI5 plasmids from Enterobacteriaceae,*Int. Microbiol.*, 2023, doi: 10.1007/s10123-022-00299-w.
83. M. Nabili and M. Moazeni, –P433 Identification of *Candida* species isolated from hospitalized patients with candiduria ,*Med. Mycol.*, 2022, doi: 10.1093/mmy/myac072.p433.
84. F. Di Toro et al., –*Rana temporaria* on montes della laga (Central Italy): Isolated population or wide distribution? first record in abruzzo and marche,*Acta Herpetol.*, 2021, doi: 10.36253/a_h-9824.
85. X. Lv et al., –Expression and antimicrobial activity of the recombinant bovine lactoferricin in *Pichia pastoris*,*Synth. Syst. Biotechnol.*, 2024, doi: 10.1016/j.synbio.2023.12.002.
86. Y. lan Chen, X. lian Bian, F. jiang Guo, Y. chun Wu, and Y. ming Li, –Two new 19-norbufadienolides with cardiotoxic activity isolated from the venom of *Bufo bufo gargarizans*,*Fitoterapia*, 2018, doi: 10.1016/j.fitote.2018.10.023.
87. K. Nishimori and M. Ouchi, –AB-alternating copolymers: Via chain-growth polymerization: Synthesis, characterization, self-assembly, and functions,*Chem. Commun.*, 2020, doi: 10.1039/d0cc00275e.
88. X. Zhang et al., –The Effect of the Antimicrobial Peptide Plectasin on the Growth Performance, Intestinal Health, and Immune Function of Yellow-Feathered Chickens,*Front. Vet. Sci.*, 2021, doi: 10.3389/fvets.2021.688611.
89. M. Corbett et al., –Tumour necrosis factor- α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: A systematic review and economic evaluation,*Health Technol. Assess. (Rockv)*, 2016, doi: 10.3310/hta20090.

90. J. S. Little, Z. F. Weiss, and S. P. Hammond, –Invasive fungal infections and targeted therapies in hematological malignancies, *Journal of Fungi*. 2021. doi: 10.3390/jof7121058.
91. R. Breitkopf, B. Tremel, T. Senoner, Z. Bukumirić, and S. Rajsic, –Invasive Fungal Breakthrough Infections under Targeted Echinocandin Prophylaxis in High-Risk Liver Transplant Recipients, *J. Fungi*, 2023, doi: 10.3390/jof9020272.
92. Gaulin et al., –Fungal Infections Associated with CD19-Targeted Chimeric Antigen Receptor T Cell Therapy, *Current Fungal Infection Reports*. 2023. doi: 10.1007/s12281-023-00460-6.
93. R. Breitkopf et al., –Incidence of Invasive Fungal Infections in Liver Transplant Recipients under Targeted Echinocandin Prophylaxis, *J. Clin. Med.*, 2023, doi: 10.3390/jcm12041520.
94. Z. Wang et al., –Peptide-Based Supramolecular Therapeutics for Fighting Major Diseases, *Advanced Functional Materials*. 2024. doi: 10.1002/adfm.202314492.
95. S. Vanpatten, M. He, A. Altit, K. F. Cheng, M. H. Ghanem, and Y. Al-Abed, –Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics, *Future Medicinal Chemistry*. 2020. doi: 10.4155/fmc-2020-0180.
96. K. Kulkarni et al., –Esterase-Mediated Sustained Release of Peptide-Based Therapeutics from a Self-Assembled Injectable Hydrogel, *ACS Appl. Mater. Interfaces*, 2021, doi: 10.1021/acsmami.1c14150.
97. R. El-Seedi et al., –Honey Bee Products: Preclinical and Clinical Studies of Their Anti-inflammatory and Immunomodulatory Properties, *Frontiers in Nutrition*. 2022. doi: 10.3389/fnut.2021.761267.
98. M. B. Brent, –Abaloparatide: A review of preclinical and clinical studies, *European Journal of Pharmacology*. 2021. doi: 10.1016/j.ejphar.2021.174409.
99. S. Andrade, M. J. Ramalho, J. A. Loureiro, and M. Do Carmo Pereira, –Natural compounds for Alzheimer's disease therapy: A systematic review of preclinical and clinical studies, *Int. J. Mol. Sci.*, 2019, doi: 10.3390/ijms20092313.
100. M. DuMont, A. Agostinis, K. Singh, E. Swan, Y. Buttle, and D. Tropea, –Sex representation in neurodegenerative and psychiatric disorders: preclinical and clinical studies, *Neurobiology of Disease*. 2023. doi: 10.1016/j.nbd.2023.106214.
101. E. Krashin, A. Piekietko-Witkowska, M. Ellis, and O. Ashur-Fabian, –Thyroid hormones and cancer: A comprehensive review of preclinical and clinical studies, *Front. Endocrinol. (Lausanne)*, 2019, doi: 10.3389/fendo.2019.00059.
102. A.O. Brightman et al., –Advancing medical technology innovation and clinical translation via a model of industry-enabled technical and educational support: Indiana Clinical and Translational Sciences Institute's Medical Technology Advance Program, *J. Clin. Transl. Sci.*, 2021, doi: 10.1017/cts.2021.1.
103. S. Okoli, T. Blix, A. I. Myhr, W. Xu, and X. Xu, –Sustainable use of CRISPR/Cas in fish aquaculture: the biosafety perspective, *Transgenic Research*. 2022. doi: 10.1007/s11248-021-00274-7.
104. P. Kumar et al., –In-vitro meat: A promising solution for sustainability of meat sector, *Journal of Animal Science and Technology*. 2021. doi: 10.5187/jast.2021.e85.
105. R. A. Mazzocchi, –Medical Sensors - Defining a Pathway to Commercialization, *ACS Sensors*, 2016, doi: 10.1021/acssensors.6b00553.
106. M. Mehta, T. A. Bui, X. Yang, Y. Aksoy, E. M. Goldys, and W. Deng, –Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development, *ACS Materials Au*. 2023. doi: 10.1021/acsmaterialsau.3c00032.
107. Liu, Z. Hao, W. J. Florkowski, L. Wu, and Z. Yang, –A Review of the Challenges Facing Global Commercialization of the Artificial Meat Industry, *Foods*, 2022, doi: 10.3390/foods11223609.
108. P. K. P. Sreenivasalu et al., –Nanomaterials in Dentistry: Current Applications and Future Scope, *Nanomaterials*. 2022. doi: 10.3390/nano12101676.
109. Renstra kemenkes, –Peraturan Menteri Kesehatan Republik Indonesia No 21 Tahun 2020 Tentang Rencana Strategis Kementerian Kesehatan 2020-2024, *Kemenkes*, 2020.
110. Ofori, P. Anjarwalla, and L. Mwaura, –ASUHAN KEPERAWATAN PADA PASIEN DENGAN GAGAL GINJAL KRONIS YANG DI RAWAT DI RUMAH SAKIT, *Molecules*, 2020.
111. A. Wateh, –Kepuasan Pasien Terhadap Pelayanan Informasi Obat Pada Swamedikasi di Apotek Merjosari Kota Malang, *Molecules*, 2020.
112. S. Syamsuddin, –HUBUNGAN EFEK SAMPING KEMOTERAPI DENGAN KUALITAS HIDUP PASIEN KANKER PAYUDARA DI RUMAH SAKIT IBNU SINA MAKASSAR, *Molecules*, 2020.
113. G. T. Pratyaksa, –New Media Sebagai Strategi Komunikasi Online Pariwisata Untuk Mempromosikan Potensi Lokal Desa Wisata Sudaji, *Molecules*, 2020.
114. R. P. Ardha, –PERLINDUNGAN HUKUM PENGGUNA MARKETPLACE DALAM HAL KEAMANAN DATA PRIBADI PENGGUNA, *Molecules*, 2020.
115. Auriantini, –HUBUNGAN PENGETAHUAN DAN PRAKTIK TERKAIT DAGUSIBU PADA IBU PKK PEDUKUHAN SUMBERJO, DESA NGALANG, GEDANGSARI, GUNUNG KIDUL, *Molecules*, 2020.